Abstract
Background:
Risk stratification in patients with papillary thyroid carcinoma (PTC) currently relies on postoperative parameters. Testing for BRAF mutations preoperatively may serve as a novel tool for identifying PTC patients at risk of persistence/recurrence after surgery.
Methods:
The study involved 185 consecutive patients with a histological diagnosis of PTC and BRAF analysis performed on thyroid fine-needle aspiration biopsy (FNAB). We assessed BRAF status in FNAB specimens obtained before thyroidectomy for PTC, and examined its association with the clinicopathological characteristics identified postoperatively, and with outcome after a mean 55±15 months of follow-up.
Results:
One hundred and fifteen of 185 (62%) PTCs carried a BRAF mutation. Univariate analysis showed that BRAF status correlated with the histological variant of PTC, cancer size, and stage at diagnosis, but not with gender, age, multifocality, or lymph node involvement. BRAF-mutated cases had a higher prevalence of persistent/recurrent disease by the end of the follow-up (11% vs. 8%), but this difference was not statistically significant. The Kaplan-Meier curve shows that among the patients with persistent/recurrent disease, BRAF-mutated patients needed a second treatment earlier than patients with BRAF wild-type, although the difference did not completely reach the statistical significance.
Conclusions:
Our study confirmed that preoperatively-identified BRAF mutation are associated with certain pathological features of PTC that correlate with prognosis. We speculate that it has a role in identifying PTCs that would generally be considered low-risk but that may reveal an aggressive behavior during their follow-up.
Acknowledgments
We thank Frances Coburn for text editing.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. J Am Med Assoc 2006;295: 2164–7.10.1001/jama.295.18.2164Search in Google Scholar
2. Leenhardt L, Grosclaude P, Cherie-Challine L. Increased incidence of thyroid carcinoma in France: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee. Thyroid 2004;14:1056–60.10.1089/thy.2004.14.1056Search in Google Scholar
3. Mazzaferri EL. An overview of the management of thyroid cancer. In: Mazzaferri EL, Harmer C, Mallick UK, Kendall-Taylor P, editors. Practical management of thyroid cancer: a multidisciplinary approach. London: Springer-Verlag, 2006:1–28.10.1007/b136179Search in Google Scholar
4. Ries LA, Melbert D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, et al. SEER Cancer Statistics Review, 1975–2004. Bethesda, MD: National Cancer Institute. Available at: http://seer.cancer.gov/csr/1975_2004/.Pdf. Assesed: November 2006.Search in Google Scholar
5. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. The American Thyroid Association Guidelines Taskforce. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006;16:109–42.10.1089/thy.2006.16.109Search in Google Scholar
6. Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, Ries LA, et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 2005;97:1407–27.10.1093/jnci/dji289Search in Google Scholar
7. Mazzaferri EL, Kloos RT. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001;86:1447–63.10.1210/jcem.86.4.7407Search in Google Scholar
8. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97:418–28.10.1016/0002-9343(94)90321-2Search in Google Scholar
9. Sherman SI, Angelos P, Ball DW, Beenken SW, Byrd D, Clark OH, et al. Thyroid carcinoma. J Natl Compr Canc Netw 2005;3: 404–57.Search in Google Scholar
10. DeGroot LJ, Kaplan EL, McCormick M, Straus FH. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 1990;71:414–24.10.1210/jcem-71-2-414Search in Google Scholar
11. Sherman SI, Brierley JD, Sperling M, Ain KB, Bigos ST, CooperDS, et al. Prospective multicenter study of thyroid carcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer 1998;83:1012–21.10.1002/(SICI)1097-0142(19980901)83:5<1012::AID-CNCR28>3.0.CO;2-9Search in Google Scholar
12. Tanaka K, Sonoo H, Hirono M, Ohkubo S, Nomura T, Ikeda M, et al. Retrospective analysis of predictive factors for recurrence after curatively resected papillary thyroid carcinoma. Surg Today 2005;35:714–19.10.1007/s00595-005-3021-8Search in Google Scholar
13. Ciampi R, Nikiforov YE. Alterations of the BRAF gene in thyroid tumors. Endocr Pathol 2005;16:163–72.10.1385/EP:16:3:163Search in Google Scholar
14. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007;28:742–62.10.1210/er.2007-0007Search in Google Scholar
15. Xing M, Tufano RP, Tufaro AP, Basaria S, Ewertz M, Rosenbaum E, et al. Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J Clin Endocrinol Metab 2004;89:2867–72.10.1210/jc.2003-032050Search in Google Scholar
16. Cohen Y, Rosenbaum E, Clark DP, Zeiger MA, Umbricht CB, Tufano RP, et al. Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules. Clin Cancer Res 2004;10:2761–5.10.1158/1078-0432.CCR-03-0273Search in Google Scholar
17. Domingues R, Mendonca E, Sobrinho L, Bugalho MJ. Searching for RET/PTC rearrangements and BRAF V599E mutation in thyroid aspirates might contribute to establish a preoperative diagnosis of papillary thyroid carcinoma. Cytopathology 2005;16:27–31.10.1111/j.1365-2303.2004.00223.xSearch in Google Scholar
18. Jin L, Sebo TJ, Nakamura N, Qian X, Oliveira A, Majerus JA, et al. BRAF mutation analysis in fine needle aspiration (FNA) cytology of the thyroid. Diagn Mol Pathol 2006;15:136–43.10.1097/01.pdm.0000213461.53021.84Search in Google Scholar
19. Chung KW, Yang SK, Lee GK, Kim EY, Kwon S, Lee SH, et al. Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cytopathology diagnosis, especially in BRAF600E mutation prevalent area. Clin Endocrinol 2006;65:660–6.10.1111/j.1365-2265.2006.02646.xSearch in Google Scholar
20. Nikiforov YE, Steward DL, Robinson-Smith TM, Haugen BR, Klopper JP, Zhu Z, et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab 2009;94:2092–8.10.1210/jc.2009-0247Search in Google Scholar
21. Kim J, Giuliano AE, Turner RR, Gaffney RE, Umetani N, Kitago M, et al. Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma. Ann Surg 2006;244:799–804.10.1097/01.sla.0000224751.80858.13Search in Google Scholar
22. Mojica WD, Khoury T. Presence of the BRAF V600E point mutation in morphologically benign appearing thyroid inclusions of cervical lymph nodes. Endocr Pathol 2006;17:183–9.10.1385/EP:17:2:183Search in Google Scholar
23. Kim TY, Kim WB, Rhee YS, Song JY, Kim JM, Gong G, et al. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol 2006;65:364–8.10.1111/j.1365-2265.2006.02605.xSearch in Google Scholar
24. Nikiforova MN, Nikiforov YE. Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn 2008;8:83–95.10.1586/14737159.8.1.83Search in Google Scholar
25. UICC: Thyroid gland. In: Sobin LH, Gospodarowicz MK, Wittekind C, editors. TNM classification of malignant rumours, 7th ed. Oxford, UK: Wiley-Blackwell Publishers, 2009:58–62.Search in Google Scholar
26. Vianello F, Mazzarotto R, Mian C, Lora O, Saladini G, Servodio O, et al. Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation. Clin Oncol (R Coll Radiol) 2012;24:162–8.10.1016/j.clon.2011.02.011Search in Google Scholar
27. Sapio MR, Posca D, Troncone G, Pettinato G, Palombini L, Rossi G, et al. Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA). Eur J Endocrinol 2006;154:341–8.10.1530/eje.1.02072Search in Google Scholar
28. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005;12:245–62.10.1677/erc.1.0978Search in Google Scholar
29. Fugazzola L, Puxeddu E, Avenia N, Romei C, Cirello V, Cavaliere A, et al. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer 2006;13:455–64.10.1677/erc.1.01086Search in Google Scholar
30. Puxeddu E, Moretti S. Clinical prognosis in BRAF-mutated PTC. Arq Bras Endocrinol Metabol 2007;51:736–47.10.1590/S0004-27302007000500011Search in Google Scholar
31. Frasca F, Nucera C, Pellegriti G, Gangemi P, Attard M, Stella M, et al. BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer 2008;15:191–205.10.1677/ERC-07-0212Search in Google Scholar
32. Fonseca E, Soares P, Rossi S, Sobrinho-Simoes M. Prognostic factors in thyroid carcinomas. Verh Dt Ges Pathol 1997;81: 82–96.Search in Google Scholar
33. Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973–1991. Cancer 1997;79:564–73.10.1002/(SICI)1097-0142(19970201)79:3<564::AID-CNCR20>3.0.CO;2-0Search in Google Scholar
34. Zatelli MC, Trasforini G, Leoni S, Frigato G, Buratto M, Tagliati F, et al. BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies. Eur J Endocrinol 2009;161:467–73.10.1530/EJE-09-0353Search in Google Scholar
35. Porra V, Ferraro-Peyret C, Durand C, Selmi-Ruby S, Giroud H, Berger-Dutrieux N, et al. Silencing of the tumor suppressor gene SLC5A8 is associated with BRAF mutations in classical papillary thyroid carcinomas. J Clin Endocrinol Metab 2005;90:3028–35.10.1210/jc.2004-1394Search in Google Scholar PubMed
36. Nikiforov YE. Molecular analysis of thyroid tumors. Mod Pathol 2011;24(Suppl 2):S34–43.10.1038/modpathol.2010.167Search in Google Scholar PubMed
37. Romei C, Fugazzola L, Puxeddu E, Frasca F, Viola D, Muzza M, et al. Modifications in the papillary thyroid cancer gene profile over the last 15 years. J Clin Endocrinol Metab 2012;97: E1758–65.10.1210/jc.2012-1269Search in Google Scholar PubMed
38. Mathur A, Moses W, Rahbari R, Khanafshar E, Duh QY, Clark O, et al. Higher rate of BRAF mutation in papillary thyroid cancer over time: a single-institution study. Cancer 2011;117:4390–5.10.1002/cncr.26072Search in Google Scholar PubMed PubMed Central
39. Kumagai A, Namba H, Saenko VA, Ashizawa K, Ohtsuru A, Ito M, et al. Low frequency of BRAFT1796A mutations in childhood thyroid carcinomas. J Clin Endocrinol Metab 2004;89:4280–4.10.1210/jc.2004-0172Search in Google Scholar PubMed
40. Penko K, Livezey J, Fenton C, Patel A, Nicholson D, Flora M, et al. BRAF mutations are uncommon in papillary thyroid cancer of young patients. Thyroid 2005;15:320–5.10.1089/thy.2005.15.320Search in Google Scholar PubMed
41. Lassalle S, Hofman V, Ilie M, Butori C, Bozec A, Santini J, et al. Clinical impact of the detection of BRAF mutations in thyroid pathology: potential usefulness as diagnostic, prognostic and theragnostic applications. Curr Med Chem 2010;17:1839–50.10.2174/092986710791111189Search in Google Scholar PubMed
42. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005;90:6373–9.10.1210/jc.2005-0987Search in Google Scholar PubMed
43. Park YJ, Kim YA, Lee YJ, Kim SH, Park SY, Kim KW, et al. Papillary microcarcinoma in comparison with larger papillary thyroid carcinoma in BRAF(V600E) mutation, clinicopathological features, and immunohistochemical findings. Head Neck 2010;32:38–45.Search in Google Scholar
44. Ugolini C, GianniniR, Lupi C, Salvatore G, Miccoli P, Proietti A, et al. Presence of BRAF V600E in very early stages of papillary thyroid carcinoma. Thyroid 2007;17:381–8.10.1089/thy.2006.0305Search in Google Scholar PubMed
45. Sedliarou I, Saenko V, Lantsov D, Rogounovitch T, Namba H, Abrosimov A, et al. The BRAFT1796A transversion is a prevalent mutational event in human thyroid microcarcinoma. Int J Oncol 2004;25:1729–35.10.3892/ijo.25.6.1729Search in Google Scholar
46. Kim TY, Kim WB, Song JY, Rhee YS, Gong G, Cho YM, et al. The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol (Oxf) 2005;63:588–93.10.1111/j.1365-2265.2005.02389.xSearch in Google Scholar PubMed
47. Knauf JA, Ma X, Smith EP, Khang L, Mitsutake N, Liao XH, et al. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res 2005;65:4238–45.10.1158/0008-5472.CAN-05-0047Search in Google Scholar PubMed
48. Lee JH, Lee ES, Kim YS. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer 2007;110:38–46.10.1002/cncr.22754Search in Google Scholar PubMed
49. Shattuck TM, Westra WH, Ladenson PW, Arnold A. Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma. N Engl J Med 2005;352:2406–12. Erratum in: N Engl J Med 2005;353:1640.10.1056/NEJMoa044190Search in Google Scholar PubMed
50. Park SY, Park YJ, Lee YJ, Lee HS, Choi SH, Choe G, et al. Analysis of differential BRAF(V600E) mutational status in multifocal papillary thyroid carcinoma: evidence of independent clonal origin in distinct tumor foci. Cancer 2006;107:1831–8.10.1002/cncr.22218Search in Google Scholar PubMed
51. Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell 2014;159:676–90.10.1016/j.cell.2014.09.050Search in Google Scholar PubMed PubMed Central
52. Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 2003;88:4393–7.10.1210/jc.2003-030305Search in Google Scholar PubMed
53. Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh QY, et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 2007;246:466–71.10.1097/SLA.0b013e318148563dSearch in Google Scholar PubMed PubMed Central
54. Sancisi V, Nicoli D, Ragazzi M, Piana S, Ciarrocchi A. BRAFV600E mutation does not mean distant metastasis in thyroid papillary carcinomas. J Clin Endocrinol Metab 2012;97:1745–9.10.1210/jc.2012-1526Search in Google Scholar PubMed
55. Xing M, Alzahrani AS, Carson KA, Shong YK, Kim TY, Viola D, et al. Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. J Clin Oncol 2015;33:42–50.10.1200/JCO.2014.56.8253Search in Google Scholar PubMed PubMed Central
56. Durante C, Montesano T, Torlontano M, Attard M, Monzani F, Tumino S, et al. PTC Study Group. Papillary thyroid cancer: time course of recurrences during postsurgery surveillance. J Clin Endocrinol Metab 2013;98:636–42.10.1210/jc.2012-3401Search in Google Scholar PubMed
57. Roti E, degli Uberti EC, Bondanelli M, Braverman LE. 2008 Thyroid papillary microcarcinoma: a descriptive and meta-analysis study. Eur J Endocrinol 2008;159:659–67.10.1530/EJE-07-0896Search in Google Scholar PubMed
58. Elisei R, Viola D, Torregrossa L, Giannini R, Romei C, Ugolini C, et al. The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. J Clin Endocrinol Metab 2012;97:4390–8.10.1210/jc.2012-1775Search in Google Scholar PubMed
©2016 Walter de Gruyter GmbH, Berlin/Boston
